Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer.

Current Time 
Duration 
Loaded: 0%
Stream Type LIVE
Remaining Time 
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected

      In this video, Barbara Burtness, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses results of E1305, a phase III randomized trial that tested chemotherapy with or without bevacizumab in patients with recurrent or metastatic squamous cell head and neck cancer.

      Burtness presented results of the study (abstract 6000) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

      Recent Videos
      Durvalumab Inferior to Cetuximab in Contraindicated Cisplatin HNSCC
      Durvalumab Inferior to Cetuximab in Contraindicated Cisplatin HNSCC
      Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
      Advocate Outlines Resources for Chronic Myeloid Leukemia Population
      Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
      Assessing the Future With “Promising” Antibody Drug Conjugates in Breast Cancer
      Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
      Mitigating ILD Following T-DXd in HR+, HER2-Low Metastatic Breast Cancer
      Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
      Ensuring Quality of Life in Chronic Myeloid Leukemia Populations
      Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
      Formulating Questions for Clinicians to Understand a CML Diagnosis
      Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
      Defining Goals of Therapy in Chronic Myeloid Leukemia
      Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
      Mitigating Toxicity and Monitoring QOL in Chronic Myeloid Leukemia
      Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
      Determining Treatment Courses for a Chronic Myeloid Leukemia Diagnosis
      Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
      Expert Highlights Potential Utility of Amivantamab in Advanced EGFR+ NSCLC
      Related Content
      Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

      Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

      Ariana Pelosci
      March 20th 2025
      Article

      Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.

      Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

      Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

      Neil M. Iyengar, MD;Paolo Tarantino, MD
      June 17th 2024
      Podcast

      Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

      Pembrolizumab/Bevacizumab Improves Efficacy in Nasopharyngeal Carcinoma

      Pembrolizumab/Bevacizumab Improves Efficacy in Nasopharyngeal Carcinoma

      Tim Cortese
      March 2nd 2025
      Article

      Pembrolizumab and bevacizumab yielded an ORR of 58.3% vs 12.5% with pembrolizumab monotherapy in patients with platinum-resistant nasopharyngeal carcinoma.

      Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

      Oncology On-The-Go Podcast: ASCO 2023 Recap

      Ritu Salani, MD;Tanios S. Bekaii-Saab, MD, FACP
      June 19th 2023
      Podcast

      Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

      Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

      Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC

      Russ Conroy
      February 20th 2025
      Article

      Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

      Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

      Cetuximab/Radiation Improves DFS in Locally Advanced SCCHN

      Russ Conroy
      February 1st 2025
      Article

      Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.